Literature DB >> 2122653

Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.

W E Haefely1, R Kettler, H H Keller, M Da Prada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2122653

Source DB:  PubMed          Journal:  Adv Neurol        ISSN： 0091-3952


× No keyword cloud information.
  5 in total

1.  Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

Authors:  M D Galva; G P Bondiolotti; M Olasmaa; G B Picotti
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 2.  Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.

Authors:  M B Youdim; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1993

3.  Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.

Authors:  N H Holford; T W Guentert; J Dingemanse; R Kettler
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

4.  Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA.

Authors:  O Cases; I Seif; J Grimsby; P Gaspar; K Chen; S Pournin; U Müller; M Aguet; C Babinet; J C Shih
Journal:  Science       Date:  1995-06-23       Impact factor: 47.728

5.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.